[6-K] BioLineRx Ltd. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

BioLineRx Ltd. filed a Form 6-K to report that it has issued a press release announcing a USPTO Notice of Allowance for a key patent covering its GLIX1 candidate for treating a broad range of cancer types. This step means the U.S. patent office has indicated it intends to grant the patent, strengthening BioLineRx’s intellectual property position around GLIX1 and its potential oncology uses.

Insights

Biotech & IP Strategy Analyst

USPTO Notice of Allowance strengthens BioLineRx’s patent position for GLIX1.

BioLineRx reports that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a key patent covering GLIX1 for treating a broad range of cancer types. A Notice of Allowance indicates the application has passed examination and the patent is expected to be granted after final administrative steps.

For a biotech company, such protection can help secure exclusivity around a drug candidate’s use and potential future revenue streams, particularly when it spans a broad range of cancer indications. The actual commercial impact will depend on GLIX1’s clinical progress and any future regulatory outcomes, which are not detailed here.

The 6-K highlights this single development without financial metrics, emphasizing intellectual property progress rather than near-term earnings effects. Subsequent disclosures on GLIX1’s clinical data and eventual patent grant details would further frame how important this protection becomes for BioLineRx’s pipeline.

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission file number: 001-35223

BioLineRx Ltd.

(Translation of registrant’s name into English)

2 HaMa’ayan Street

Modi’in 7177871, Israel

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the registrant’s press release issued on November 17, 2025, titled “BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types.”

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types.”

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BioLineRx Ltd.
	By:	/s/ Philip A. Serlin
		Philip A. Serlin
		Chief Executive Officer

Dated: November 17, 2025

FAQ

What did BioLineRx (BLRX) announce in this Form 6-K?

BioLineRx reported that it issued a press release announcing a USPTO Notice of Allowance for a key patent covering its GLIX1 candidate for treating a broad range of cancer types.

What is the significance of the USPTO Notice of Allowance for BioLineRx’s GLIX1?

A Notice of Allowance from the USPTO means the patent application for GLIX1 has been approved for grant, reinforcing BioLineRx’s intellectual property protection around GLIX1’s use in a broad range of cancer types, subject to completion of administrative steps.

Which product candidate is covered by the new BioLineRx patent allowance?

The Notice of Allowance relates to a key patent covering GLIX1 for treating a broad range of cancer types.

Does this BioLineRx Form 6-K include financial or earnings information?

No, this Form 6-K focuses on the intellectual property development related to GLIX1 and does not present earnings, revenue, or other financial performance data.

Is the full BioLineRx press release on the GLIX1 patent included with the filing?

Yes. The Form 6-K states that the press release titled “BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types” is attached as Exhibit 99.1.